Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
/ C9 V' u! I! b3 O" S9 C1 _( K1 m0 d! U& G5 u' [' i7 m
) t4 S3 h) T: L }/ o+ w6 G
Sub-category:
3 \* \5 R: T4 ?/ QMolecular Targets
$ k) F! C- j( j+ L$ E3 W
" u$ G! c- C7 p- n) r! Z2 K# A( Z+ Y$ ?0 {
Category:
9 ~5 o% t$ J: R0 Q- CTumor Biology 9 Z% ^% R% S, H( i6 Z- g
4 m# ]- ]$ G" w. u+ O/ D( s
3 S' R% _( b' F, Y. E/ E
Meeting:
2 x8 n7 o1 F0 M# y% a; J2011 ASCO Annual Meeting
& \ Q4 A0 q. |0 F; f; D6 S) x; H( _
N6 F( o$ }: s. ?" |: j3 @Session Type and Session Title:
/ P' y8 m+ E/ F6 N q ePoster Discussion Session, Tumor Biology
0 J/ r& r6 g1 b, _7 d# x
; p s! x. d M6 A( L' y# q/ y6 L* m. x" `7 m" q/ [
Abstract No:! C: ]7 _, H' m$ z
10517
0 y; }. i4 G; e u5 \
1 T3 K2 E' N: p# N
" G& x0 c9 d- \3 ^) n6 r% I4 B$ Z* {Citation:9 u: M: B9 K5 Z" _0 z$ q" u
J Clin Oncol 29: 2011 (suppl; abstr 10517)
2 e% A6 b5 ~6 c9 T4 N3 H1 W
3 @# ^) P9 p8 @5 m; r( l* u
" l4 J" t' ~' U* ^Author(s):
5 K8 Q+ H4 r$ I4 l; AJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
- z2 F8 h" Q) L0 t4 [+ E2 H7 @ `: I" I( u# p* J
* o6 w; K* Q( Z3 x) t8 C) z" t
9 Z1 F9 z1 ] Q0 X: W
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings." @9 U0 Y% x9 I- U6 I- J# `/ P9 E
% j+ ]; ^+ r, @9 |1 N0 bAbstract Disclosures8 |/ s6 f8 m6 j7 n" }7 ~
& S7 [8 G; w: c- U; j. pAbstract:) v4 n" P6 F- \' X% b" N
+ i/ v4 _1 ?8 K+ r
6 }1 ]) O5 R# L$ _/ ]Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
8 V& V |7 Q) m1 s7 d. S5 U6 [ m' ?
% z7 A8 ~) {' V0 q9 { |